Ashland Global Holdings Inc

3 sept 2024, 11:00 UTC

Ashland Completes Sale of Nutraceuticals Business to Affil of Turnspire Capital Partners >ASH

6 ago 2024, 21:04 UTC

Ashland Sees FY Sales $2.1B >ASH

6 ago 2024, 21:03 UTC

Ashland Sees 4Q Sales $530M-$540M >ASH

6 ago 2024, 21:03 UTC

Ashland 3Q Adj EPS $1.49 >ASH

6 ago 2024, 21:02 UTC

Ashland 3Q Sales $544M >ASH

6 ago 2024, 21:02 UTC

Ashland 3Q Cont Ops EPS 60c >ASH

6 ago 2024, 21:02 UTC

Ashland 3Q EPS 12c >ASH

6 ago 2024, 21:02 UTC

Ashland Issues Outlook for 4Q and Full-Yr Fiscal 2024

7 may 2024, 11:01 UTC

Ashland: Transaction Is Expected to Close in 3Q >ASH

7 may 2024, 10:59 UTC

Ashland Signs Definitive Agreement to Sell Nutraceuticals Business to Turnspire Capital Partners >ASH

30 ene 2024, 22:04 UTC

Ashland Sees FY Sales $2.15B-$2.25B >ASH

30 ene 2024, 22:04 UTC

Ashland Sees 2Q Sales $565M-$585M >ASH

30 ene 2024, 22:04 UTC

Ashland: Current Demand Patterns Suggest a Potential Recovery With Continued Momentum Into the 2H of the Fiscal Yr >ASH

30 ene 2024, 22:03 UTC

Ashland 1Q EPS 51c >ASH

30 ene 2024, 22:03 UTC

Ashland 1Q Sales $473M >ASH

8 nov 2023, 22:03 UTC

Ashland Sees 1Q Sales $470M-$490M >ASH

8 nov 2023, 22:02 UTC

Ashland 4Q Loss/Shr 7c >ASH

8 nov 2023, 22:02 UTC

Ashland 4Q Sales $518M >ASH

1 nov 2023, 21:08 UTC

Ashland: Ongoing Free Cash Flow of $104M in the Qtr >ASH

1 nov 2023, 21:08 UTC

Ashland: Inventory Reduction of $86M Compared to June 30 >ASH

1 nov 2023, 21:08 UTC

Ashland: Sees Adjusted EBITDA of $74M for Qtr and $459M for Full Yr Including Approximately $58M of Inventory-Control Actions During the Fiscal 4Q >ASH

1 nov 2023, 21:08 UTC

Ashland: Sees Net Loss (Including Discontinued Operations) of $4M for Qtr, Net Income (Including Discontinued Operations) of $178M for Full Yr >ASH

1 nov 2023, 21:04 UTC

Ashland Sees 2023 Sales $2.19B >ASH

1 nov 2023, 21:03 UTC

Ashland Sees 4Q Sales $518M >ASH